Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02068599 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee

A Phase 2 study of Osteoarthritis of the Knee, sponsored by Teva Branded Pharmaceutical Products R&D.

Completed
Registry status
Phase 2
Development phase
389
Enrollment target
20
Study locations

NCT02068599 is a Phase 2 study of Osteoarthritis of the Knee that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 389 participants, above the 195-participant average among 15 other Osteoarthritis of the Knee trials with a reported enrollment target (99% higher). The trial reports 20 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02068599, a Phase 2 study of Osteoarthritis of the Knee, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.

COMPLETED
Registry status
Phase 2
Development phase
389 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of the study is to evaluate the change from baseline after 4 weeks of topical administration of TV-45070 (4% and 8% ointment) compared with placebo for the relief of symptoms of primary OA affecting a single knee

Conditions Studied

Osteoarthritis of the Knee

Interventions

  • DRUG Placebo
  • DRUG TV-45070

Study Locations (20)

Florida

  • Teva Investigational Site 12256 - Clearwater
  • Teva Investigational Site 12241 - DeLand
  • Teva Investigational Site 12246 - Eustis
  • Teva Investigational Site 12231 - Fort Myers
  • Teva Investigational Site 12216 - Hialeah
  • Teva Investigational Site 12230 - Jacksonville
  • Teva Investigational Site 12220 - Miami
  • Teva Investigational Site 12221 - Oldsmar
  • Teva Investigational Site 12226 - Orlando
  • Teva Investigational Site 12237 - Orlando
  • Teva Investigational Site 12255 - Ormond Beach
  • Teva Investigational Site 12225 - Plantation

California

  • Teva Investigational Site 12217 - Anaheim
  • Teva Investigational Site 12244 - Anaheim
  • Teva Investigational Site 12252 - Cerritos
  • Teva Investigational Site 13009 - Cerritos
  • Teva Investigational Site 12233 - El Cajon
  • Teva Investigational Site 12240 - Lomita
  • Teva Investigational Site 12251 - Sacramento
  • Teva Investigational Site 12234 - Spring Valley

Trial Details

FieldValue
Enrollment Target 389 participants
Start Date 2014-04-14
Est. Completion 2015-05-04
Phase Phase 2

Sponsor

Teva Branded Pharmaceutical Products R&D

167 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02068599

The ClinicalTrials.gov registry entry for NCT02068599 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 389 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 195-participant average among 15 other Osteoarthritis of the Knee trials with a reported enrollment target (99% higher). The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoarthritis of the Knee appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02068599 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Florida, California.

Frequently Asked Questions

What is clinical trial NCT02068599 about?

NCT02068599 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee". The primary purpose of the study is to evaluate the change from baseline after 4 weeks of topical administration of TV-45070 (4% and 8% ointment) compared with placebo for the relief of symptoms of primary OA affecting a single knee

What is the current status of trial NCT02068599?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 389 participants. The study started on 2014-04-14. Estimated completion is 2015-05-04.

What conditions does trial NCT02068599 study?

This clinical trial studies the following conditions: Osteoarthritis of the Knee.

What interventions are being tested in trial NCT02068599?

The interventions under investigation include: Placebo (DRUG), TV-45070 (DRUG).

Who is sponsoring clinical trial NCT02068599?

This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02068599 being conducted?

This trial has 20 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Osteoarthritis of the Knee

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Osteoarthritis of the Knee

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.